Illinois Society for Advanced Practice Nursing honors Take Care Clinic NP Penny Strong
CHICAGO — The Illinois Society for Advanced Practice Nursing has recognized Penny Strong, nurse practitioner at Walgreens’ Take Care Clinic in River Forest, Ill., with its Marie Lindsey Spirit of Advanced Practice Nursing award during the Illinois Nurses Association biennial convention.
The convention was held in East Peoria, Ill., from Oct. 20 to 22. The award is named after Marie Lindsey, PhD, APN, CNP, who was the first president of ISAPN and a driving force in the pursuit of legislation to recognize APNs in Illinois.
The award is given by the Illinois Society for Advanced Practice Nursing to a licensed advanced practice nurse in Illinois whom exemplifies the characteristics of leadership, commitment and achievement in advanced practice nursing. “Penny Strong is committed to the nurse practitioner role in two capacities: as a preceptor of students and as a colleague in clinical practice,” Strong’s Take Care Clinic colleague Charlie Yingling said. Strong advocated for the Take Care Clinics to serve as training sites for nurse practitioner students. Yingling credited Strong as the driving force behind the Take Care Clinic’s nurse practitioners move to unionize.
“When our employer made unilateral changes in the way were allowed to practice our profession, Penny was the first person to step up and say something. Following her leadership, countless other colleagues found the courage to step forward and demand a restoration of NP autonomy over the clinical practice, which eventually led to the formation of the Take Care Clinic union,” Yingling added.
Strong ultimately led the group to seek out collective bargaining representation from the Illinois Nurses Association. Strong is on the Take Care Clinic negotiating team and president of the board. Before coming to the Walgreens’ Take Care Clinic, Strong worked as a family nurse practitioner at the University of Illinois at Chicago Medical Center from November 2004 to July 2007; as a registered nurse at Rush Oak Park Hospital from May 2001 to November 2004; and a nurse clinician at University Consultant in Allery and Immunology at Rush University Medical Center from August 1999 to April 2001.
Rite Aid launches Rite Track Diabetes Tour
CAMP HILL, Pa. — Rite Aid is collaborating with LifeScan to bring free diabetes testing, resources and materials to communities across the Northeast, the retail pharmacy chain said Friday.
The Rite Track Diabetes Tour will start in New York on Tuesday at 11 a.m. to mark American Diabetes Month. Chef Sam Talbot, who has Type 1 diabetes, will be aboard the bus to share his diabetes story and give away signed copies of his newly published cookbook, "The Sweet Life: Diabetes Without Boundaries."
At every tour stop, attendees can step into the bus for a complimentary blood-glucose test to help identify their risk for developing diabetes or an A1C test, which shows a person living with diabetes their average blood glucose over the past three months. They also can speak with a Rite Aid pharmacist about their test results and learn about Rite Aid’s resources for people with diabetes. The 30 stops on the tour also will include Boston; Philadelphia; Washington; Pittsburgh; Harrisburg, Pa.; Buffalo, N.Y.; and Norfolk, Va.
"The Rite Track Diabetes Tour is a great way for us to offer additional support to people with diabetes, whether they’ve been living with diabetes forbears or have just recently been diagnosed," Rite Aid EVP pharmacy Robert Thompson said. "We want them to know they aren’t alone and that their Rite Aid pharmacists can help them successfully manage and live well with diabetes."
In addition, Rite Aid’s philanthropic arm, the Rite Aid Foundation, will donate a total of $20,000 to local American Diabetes Association chapters.
Pfizer completes Icagen acquisition
NEW YORK — Icagen officially is a wholly owned subsidiary of Pfizer.
As part of the transaction, which first was announced in July, Icagen now will be part of Pfizer’s worldwide research and development organization and also will be integrated into Neusentis, Pfizer’s pain, sensory disorders and regenerative medicine research unit.
The aggregate transaction value, which includes the value of the shares that already were owned by Pfizer, was about $56 million.
“We’re excited that Icagen, a global leader in pain research, has now joined Pfizer,” said Ruth McKernan, Pfizer SVP and chief scientific officer of Neusentis. “We have worked closely with Icagen for several years and have the utmost respect for their expertise. Their understanding of ion channel mechanisms will enhance our ability to develop novel drugs for the treatment of pain and related disorders.”